GDRXGoodRx Holdings, Inc.
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for a decline (~−11% a year). The price bakes in little to no growth.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What GDRX's price assumes
GoodRx Holdings, Inc. trades at 84.5× earnings against 45.1× for the median Health Information Services name, more expensive than its own group.
Trailing P/E · Health Information Services median 45.1 · 1.87× the median: the market pays up for this one
- Price / sales
- 0.26
Price / sales · as of 2026-Q1
- Free cash flow yield
- 17%
Free cash flow yield · Health Information Services median 6.3%
- Growth the price implies
- −11%
Growth the price implies · The price pays for −11% free cash flow growth a year for a decade; the business has delivered +16% a year over the last three.
Details›
- Price / bookas of 2026-Q1
- 0.33
- EV / EBITas of 2026-Q1
- 6.54
- EV / salesas of 2026-Q1
- 0.65
- Healthcare median P/E509 names
- 26.0
- Health Information Services median P/E25 names
- 45.1
- Free cash flow, trailing twelve months
- $197M
- Market capitalisation
- $1.14B
- 3-year revenue growth
- +1.8%
- 3-year free cash flow growth
- +16%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Health Information Services
Ranks #5 of 20 by RyuScore